Bharat Biotech's COVID-19 vaccine, 'COVAXIN' has demonstrated an interim vaccine efficacy of 80.6% in its Phase 3 clinical trial.
"Today is an important day for us, country and Indian science.
COVAXIN has demonstrated an interim vaccine efficacy of around 80.6% in its Phase 3 clinical trial.
The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with ICMR," Bharat Biotech chairman Dr Krishna Ella.
